Update and harmonisation of guidance for the management of diabetic ketoacidosis in children and young people in the UK by Rugg-Gunn, Charlotte EM et al.
1Rugg- Gunn CEM, et al. BMJ Paediatrics Open 2021;5:e001079. doi:10.1136/bmjpo-2021-001079
Open access 
Update and harmonisation of guidance 
for the management of diabetic 
ketoacidosis in children and young 
people in the UK
Charlotte EM Rugg- Gunn   ,1,2 Mark Deakin,3 Daniel B Hawcutt2,4 
To cite: Rugg- Gunn CEM, 
Deakin M, Hawcutt DB. 
Update and harmonisation of 
guidance for the management 
of diabetic ketoacidosis in 
children and young people in 
the UK. BMJ Paediatrics Open 
2021;5:e001079. doi:10.1136/
bmjpo-2021-001079
Received 2 March 2021
Accepted 21 May 2021
1University of Liverpool School 
of Medicine, Liverpool, UK
2Department of Women's and 
Children's Health, University of 
Liverpool, Liverpool, UK
3Alder Hey Children’s Hospital, 
Liverpool, UK
4NIHR Alder Hey Clinical 
Research Facility, Liverpool, UK
Correspondence to
Dr Daniel B Hawcutt;  
dhawcutt@ liverpool. ac. uk
Review
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Diabetic ketoacidosis (DKA) is a life- threatening 
complication of type 1 diabetes mellitus. Careful and timely 
intervention is required to optimise glycaemic control and 
reduce the risk of mortality and devastating complications. 
Of these, cerebral oedema is the leading cause of death, 
with a mortality rate of approximately 25%. This article 
highlights the recent updates to UK fluid therapy guidelines 
for DKA and provides clinical context for the benefit of 
paediatricians and junior doctors in light of this new 
guidance.
INTRODUCTION
Diabetic ketoacidosis (DKA) is a potentially 
life- threatening metabolic complication of 
type 1 diabetes mellitus. Despite interventions 
to reduce the incidence of DKA, the National 
Paediatric Diabetes Audit for 2018/2019 
showed that overall 20.9% of all newly diag-
nosed patients in the United Kingdom (UK) 
presented in DKA, although there is consider-
able regional variability.1
DKA is characterised by uncontrolled 
hyperglycaemia, ketosis and subsequent 
metabolic acidosis. As highlighted in figure 1, 
the clinical picture can develop insidiously 
due to a variable constellation of non- specific 
systemic signs and symptoms, including poly-
uria, polydipsia, weight loss, fatigue, vomiting 
and abdominal pain, ultimately leading to 
confusion, coma and death, if untreated.2 3 
Due to the ambiguity of the presenting clin-
ical features in the early stages, delays in diag-
nosis are common.4
Globally, the International Society for 
Paediatric and Adolescent Diabetes (ISPAD) 
guidelines are widely used for management 
of paediatric DKA.5 However, in the UK, it 
is guided by the integrated care pathways 
of either the British Society for Paediatric 
Endocrinology and Diabetes (BSPED) or 
the National Institute for Health and Care 
Excellence (NICE). The BSPED guideline 
evolved from the NICE guideline in 2009 due 
to concerns over limited evidence that was 
used for its development. While there were a 
number of dual- serving board members, the 
input and additional evidence by the BSPED 
special interest group in DKA was thought to 
increase its safety.6 Both guidelines cover the 
diagnosis and management of type one and 
two diabetes in children and young people 
(CYP) aged under 18 years.7 Areas of partic-
ular benefit within a secondary care setting 
are centred on the requirements for fluid 
therapy, given the importance of resuscita-
tion in preventing complications. Due to 
the difference in perceived risk of cerebral 
oedema (CO) due to rapid fluid adminis-
tration, there was discordance between the 
NICE and BSPED 2015 guidelines.
Specifically, the NICE 2015 guidelines 
were more conservative with fluid adminis-
tration, in order to avoid rapid changes in 
osmolality. The BSPED guidelines permitted 
a more generous fluid allowance, and this 
raised concerns about precipitating CO. The 
conflicting advice generated challenges in the 
emergency setting, with arbitrary site- specific 
preference rather than evidence- based 
medicine taking precedence. In addition to 
Key messages
 ► Updates to two UK guidelines in 2020 has improved 
concordance, with 0.9% sodium chloride and the 
Holliday- Segar formula used as a gold standard to 
calculate fluid maintenance requirement.
 ► Minor differences remain, such as the maximum 
weight for maintenance and the stratification of dia-
betic ketoacidosis or dehydration severity.
 ► Careful monitoring and adherence to these national 
guidelines is recommended and will hopefully con-
tribute to a reduction in deaths secondary to cere-
bral oedema (CO).
 ► Further research is required to evaluate the efficacy 
of these new guidelines, and better understand the 
pathophysiology and risk factors for developing CO.
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generating uncertainty of treatment pathways increasing 
the risk of clinical error, the regional variability hampered 
service evaluation and audit of clinical practice.
Unfortunately, there is little data to establish differ-
ences in their efficacy, especially surrounding the risk of 
CO in the paediatric population. However, inadequate 
resuscitation is likely to increase the risk of brain injury 
and thus must be avoided. Further research on a national 
scale is required to assess this.
This article aims to highlight the considerable alter-
ations made to the two main UK guidelines. Alongside 
these updates, this article will provide clinical context to 
paediatricians and junior doctors who are likely to treat 
these vulnerable groups.
UPDATED GUIDANCE
In January 2020, the BSPED published new guidance 
for the management of children with DKA.6 This inte-
grated care pathway migrated further from the model of 
restrictive fluid replacement towards an even more flex-
ible approach for resuscitative and maintenance fluids. 
The rationale for this was based on new evidence from 
the Pediatric Emergency Care Applied Research Network 
(PECARN) DKA Fluid trial, which suggested that there 
was no significant difference in outcomes between rapid 
and slower fluid administration.8 Additionally, it showed 
that the initial conscious level was closely related to pH 
and weakly to age, but not to blood glucose or plasma 
sodium level.8 9 While this appears to demonstrate that 
cerebral function is related to the severity of acidosis 
even in the absence of drivers of CO, it does not negate 
previous evidence that fluid shift may also contribute 
towards CO.10 11
Furthermore, there are clear risks associated with 
inadequate fluid replacement. A hypovolaemic state 
will result in systemic hypotension and ultimately, cere-
bral hypoperfusion which, particularly in the context of 
acidosis, will increase the risk of a brain injury.6
In 2008, following three deaths from CO, the South 
Thames Retrieval Service introduced a ‘restrictive fluid’ 
DKA guideline in the region. Subsequently, no deaths 
have been reported, but this is insufficient evidence 
on which to make definitive recommendations or 
guidelines.12
More recently, in December 2020, NICE released 
updated guidance on the management of DKA in CYP, 
which was broadly concordant with BSPED, particularly 
with respect to more liberal fluid restriction. This was 
prompted by new evidence identified by NICE’s surveil-
lance team in a review of 12 studies set to determine 
optimal fluid therapy in CYP with DKA. The fluid proto-
cols followed in the PECARN study were fundamental 
to these updates,8 as ‘neither the rate of administration 
nor the sodium chloride content of intravenous fluids 
significantly influenced neurologic outcomes in children 
with DKA’.8 Therefore, restrictions to the fluid admin-
istration, which were recommended in the 2015 NICE 
guidance, ‘were not necessarily required’.13 Additionally, 
as with the BSPED and ISPAD guidelines, the updated 
NICE guidance was amended to include the Holliday- 
Segar formula, used to calculate fluid maintenance.6 7 
Updates to both the BSPED and NICE guidelines in 2020 
have a more permissive fluid rate than in the previous 
DKA fluid therapy guidelines.
Both BSPED and NICE recommend the following fluid 
maintenance requirements, using 0.9% sodium chloride 
without added glucose, and the Holliday- Segar formula:
 ► 100 mL/kg for the first 10 kg (0–10 kg body weight).
Figure 1 Key signs and symptoms of diabetic ketoacidosis, 
adapted from Schnabel and Hedrich.1
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 ► 50 mL/kg for the second 10 kg (10–20 kg body 
weight).
 ► 20 mL/kg for each subsequent kilogramme (>20 kg 
body weight).
 ► When calculating the total fluid replacement, subtract 
any initial bolus volumes from the total fluid deficit 
(unless the child or young person is in shock).
For insulin and electrolyte replacement requirements, 
both recommend6 7:
 ► The addition of 40 mmol/L potassium chloride to 
all fluids (apart from the initial intravenous bolus) 
unless the patient is anuric or hyperkalaemic. Include 
this before starting the insulin infusion if hypokala-
emia is observed at presentation.
 ► 0.9% sodium chloride should be used without added 
glucose unless the plasma glucose is <14 mmol/L.
 ► Initially assess for the presence of hyponatraemia, 
continue to monitor throughout treatment and treat 
as soon as blood glucose falls. Monitor sodium levels 
throughout treatment and calculate sodium initially 
to identify if hyponatraemia is present. This should be 
treated as soon as blood glucose falls. It is important 
to monitor as hyponatraemia and rapidly increasing 
sodium levels can both be signs of CO.
 ► Do not give intravenous sodium bicarbonate to CYP 
with DKA unless they have compromised cardiac 
contractility caused by life- threatening hyperkalaemia 
or severe acidosis, and you have discussed with paedi-
atric intensivist.
 ► A soluble insulin infusion of between 0.05 units/kg/
hour and 0.1 units/kg/hour, 1–2 hours after intra-
venous fluids have been commenced. BSPED stated 
that the 0.05 units/kg/hour should be sufficient 
unless the patient is suffering from severe DKA or is 
an adolescent. If they are attached to a ‘continuous 
subcutaneous insulin infusion’, disconnect when 
starting intravenous insulin therapy. For patients 
already on long- acting insulin, it may be continued, 
and in new patients consider commencing long- 
acting subcutaneous insulin alongside intravenous. 
Similarly, the NICE guidelines state that continuing 
subcutaneous basal insulin in a child or young person 
who was using a basal insulin before DKA may be 
continued in discussion with a diabetes specialist.
Although these guidelines now have greater cohesion, 
a number of minor differences remain1 6:
 ► Regarding fluid replacement, NICE have included 
two levels of severity of DKA, while BSPED have subdi-
vided the stratification to include three discrete cate-
gories for severity and subsequent dehydration status, 
as outlined in table 1.
 – A difference remains between the maximum 
weight considered by the guidelines when calculat-
ing fluid deficit. Given that the maximum weight 
considered for each is 75 kg for NICE and 80 kg for 
BSPED, the maximum difference in deficit fluids 
could be 1850 mL (5%×75 kg=3750 mL for NICE 
compared with 7%×80 kg=5600 mL for BSPED).
 ► For patients who are clinically dehydrated, but not 
in shock, an intravenous 10 mL/kg bolus of 0.9% 
sodium chloride is recommended on admission. 
This should be administered over 30 min (NICE) or 
60 min (BSPED). This volume is included in the fluid 
replacement when calculating the total fluid deficit. 
NICE recommend discussing with a paediatrician 
experienced in DKA management before giving more 
than one intravenous bolus. A second bolus should 
only be considered if needed to improve tissue perfu-
sion and this must be done after reassessing their clin-
ical status.
 – A delicate balance between increasing the risk of 
osmolar shift secondary to rapid fluid administra-
tion, with the risk of dehydration and subsequent 
CO due to slower fluid administration, is the foun-
dation for the initial discrepancy between the two 
guidelines. Guidance from the 2018 ISPAD consen-
sus states that this should be administered between 
30 min and 60 min, which falls between the two UK 
guidelines.5 Therefore, aiming to administer the 
fluid rapidly but observing for signs of potential 
deterioration and adjusting the rate accordingly 
will provide the best outcome for patients.
 ► In the presence of hypovolaemic shock, both NICE 
and BSPED recommend an intravenous 0.9% sodium 
chloride bolus of 20 mL/kg. BSPED recommend 
repeating these infusions over 15 min to a maximum 
of 40 mL/kg, before considering the introduction of 
inotropes, while NICE recommends administering it 
as soon as possible. In both guidelines, the bolus for 
shock is not subtracted from total fluid deficit.
 – While the nomenclature varies between these 
two guidelines, in practice, it is likely that these 
Table 1 Comparison of NICE and BSPED DKA classification and dehydration status
Guidelines Severity of DKA Dehydration




BSPED Mild (venous pH: 7.2–7.29 or bicarbonate: <15 mmol/L)
Moderate (venous pH: 7.1–7.19 or bicarbonate: <10 mmol/L)




BSPED, British Society for Paediatric Endocrinology and Diabetes; DKA, diabetic ketoacidosis; NICE, National Institute for Health and Care 
Excellence.
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will represent similar time frames. Administering 
a 20 mL/kg 0.9% sodium chloride bolus to treat 
shock as quickly as possible should provide the best 
therapy for the patient.
 ► When calculating fluid replacement, the NICE 
guidelines recommend a maximum weight of 75 kg, 
whereas BSPED recommend a maximum weight of 
80 kg or 97th centile weight for age (whichever is 
lower).
 – This discrepancy is unlikely to be encountered 
on a frequent basis in general paediatric practice. 
However, if the weight greatly exceeds 75 kg, it may 
be more appropriate for young people to be man-
aged according to adult guidelines due to their 
increased body habitus. Additionally, identifying a 
CYP on the 97th centile can be difficult, especially 
in an emergency setting, and, therefore, this may 
be missed.
Figure 2 highlights the key similarities and differences 
between the updated 2020 guidelines.
COMPARISON TO INTERNATIONAL GUIDANCE
The new guidelines released by both NICE7 and BSPED6 
read similarly to those of non- UK- based origin. The 2018 
consensus guidelines released by ISPAD5 in conjunction 
with the European Society for Paediatric Endocrinology 
and the Lawson Wilkins Paediatric Endocrine Society are 
used globally as standard guidelines for paediatric DKA 
management. Although the updated NICE and BSPED 
guidelines are very similar, as reviewed in figure 2, the 
BSPED guidelines appear to be most similar to the ISPAD 
guidelines on fluid resuscitation and electrolyte balance, 
with very few differences between the two.
The most pertinent similarities between the BSPED 
and ISPAD guidelines include giving a bolus for shock 
(20 mL/kg), using the Holliday- Segar formula to deter-
mine the maintenance fluid requirements, using a 
maximum of 80 kg in weight for these calculations and 
stratifying the severity of DKA (into mild, moderate and 
severe) compared with the two classifications used by 
NICE (mild/moderate and severe).
In contrast to the NICE and BSPED guidelines, which 
state that a 0.9% sodium chloride solution must be used 
when considering fluid requirements, in the ISPAD 
guidance, either a 0.45% or 0.9% sodium chloride or a 
balanced salt solution (Ringer’s lactate, Hartmann’s solu-
tion or Plasma- Lyte) may be used. This is secondary to 
recent findings from randomised control trials showing 
no difference in cerebral injury in patients rehydrated at 
different rates with either 0.45% or 0.9% sodium chloride. 
Additionally, for those not in shock, these fluids should 
be infused over 30–60 min, which falls between the two 
2020 guidelines (NICE states to give fluids over 30 min 
and BSPED states over 60 min). Regarding the fluid bolus 
for those in shock, as with the NICE 2020 guidelines, the 
ISPAD guidelines state that it should be given ‘as soon 
as possible’. Conversely, BSPED says this should be over 
15 min. However, in practice, this difference in nomen-
clature is likely to be negligible. Also, in agreement with 
the NICE 2020 guidelines, the ISPAD guidelines recom-
mend the prescription of insulin at between 0.05 units/
kg/hour and 0.1 units/kg/hour, where 0.05 units/kg/
hour is usually sufficient in mild DKA. When assessing 
glucose introduction, the ISPAD guidance recommends 
that healthcare professionals ‘consider adding glucose 
before 17 mmol/L if falling rapidly. Otherwise 5% 
glucose should be added when the plasma glucose falls 
to approximately 14–17 mmol/L’. This is in contrast to 
the NICE and BSPED guidelines, which only introduce 
5% glucose when it has fallen below 14 mmol/L.
The Royal Children’s Hospital (RCH) in Melbourne, 
Clinical Practice Guidelines for Diabetic Ketoacidosis, 
last updated in November 2018, have been adapted for 
statewide use with the support of the Victorian Paedi-
atric Clinical Network. Although broadly similar, there 
are a few distinct differences between the RCH guide-
lines and those of NICE, BSPED and ISPAD. For those 
in shock, a 10 mL/kg 0.9% sodium chloride bolus can 
be given, half the volume of 20 mL/kg recommended 
by the other guidelines. Although initial fluid rates are 
based on a degree of dehydration (with the RCH strat-
ifications varying from the other guidelines: mild≤4%, 
moderate=4%–7% and severe≥7%), maintenance fluids 
are not calculated using the Holliday- Segar formula. 
Instead a detailed table is used, with the fluid require-
ments classified according to the different degrees of 
dehydration up to a maximum of 70 kg.
However, as with the other guidelines, 40 mmol/L of 
potassium chloride is added to the fluid, as long as the 
child is not anuric or a serum potassium ≥5.5 mmol/L. 
If required, these can be increased to a maximum of 
60 mmol/L, which is not specified in the other guide-
lines. Additionally, 5% glucose is added if the blood 
glucose is ≤15 mmol/L, which is comparable, although 
this can be increased to 10% glucose if blood glucose is 
falling rapidly or ≤5 mmol/L. Insulin infusion rate of 0.1 
units/kg/hour is recommended unless treating children 
under 5 years of age, children undergoing inter- hospital 
transfer (where limited access to biochemical moni-
toring) or children with blood glucose <15 mmol/L at 
the time of commencement of the insulin infusion. This 
is placed at the upper end of the bracket of the other 
guidelines, where 0.1 units/kg/hour is recommended 
for those with severe DKA, adolescence or unresolved 
ketosis.
CONCLUSIONS AND RECOMMENDATIONS
The convergence of the NICE and BSPED guidelines is 
a welcome development in the emergency management 
of paediatric DKA. This will provide much needed clarity 
to the treating clinicians, reducing regional variation and 
decreasing the potential for error. Despite the pathophys-
iology of CO remaining uncertain, fluid therapy must be 
carefully controlled, as inadequate resuscitation is likely 
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to increase the risk of brain injury and thus must be 
avoided.
There is emerging evidence for a more judicious 
approach in the management of DKA9 and the NICE 
and BSPED guidelines are now largely concordant in this 
regard. A number of minor differences in the guidelines 
remain, but these are unlikely to profoundly influence 
patient management or outcomes. As both guidelines 
have changed considerably since their conception, and 
now have only minor differences, it could be argued that 
there is no benefit of two guidelines. The existence of 
two guidelines in the UK is primarily historical, with both 
Figure 2 Flowchart demonstrating the similarities and differences between the 2020 updated guidelines. BSPED, British 
Society for Paediatric Endocrinology and Diabetes; DKA, diabetic ketoacidosis; NICE, National Institute for Health and Care 
Excellence.
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guideline- producing groups having good reason to be 
interested in this area. However, the UK would, in our 
opinion, be better served with a single set of guidance to 
avoid confusion and harmonise practice.
Despite this, it is imperative that the incidence of CO 
continues to be monitored following a change to the 
guidelines and, in addition, this may offer insights into 
the underlying pathophysiological basis and effective 
preventative measures.
In the meantime, for junior clinicians treating DKA 
in CYP, close supervision by experienced paediatri-
cians, careful monitoring and adherence to a single- set 
of evidence- based guidelines are likely to translate into 
better outcomes for this challenging condition.
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